---

Drug combination may provide option to patients with NSCLC ineligible for bevacizumab

April 03, 2012

CHICAGO - A combination of nab-paclitaxel and carboplatin for the treatment of non-small cell lung cancer may be a promising option for patients ineligible for treatment with bevacizumab, according to data presented at the AACR Annual Meeting 2012, held here March 31 - April 4.

"The combination of carboplatin and nab-paclitaxel demonstrates promising efficacy with tolerable toxicity in patients with non-small cell lung cancer (NSCLC) ineligible for therapy with bevacizumab," said Gregory A. Otterson, M.D., professor of internal medicine, co-director of the thoracic oncology program and associate director of the hematology and medical oncology fellowship program at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute in Columbus, Ohio.

Otterson and colleagues evaluated the drug combination in 63 patients with advanced NSCLC. Seventy-six percent of patients had squamous histology, making them ineligible for bevacizumab. Other contraindications for bevacizumab among this patient population included hemoptysis, thrombosis and therapeutic anticoagulation. Researchers assigned patients to 300 mg/m2/AUC6, which was later adjusted to 260 mg/m2/AUC6 due to excess neuropathy, every 21 days.

Researchers found an overall response rate of 41 percent among 53 patients available for evaluation. An additional 39 percent of patients had stable disease for at least six weeks. Disease progressed in 19 percent of patients.

"We have been surprised at the durability of response with some patients not requiring further treatment for at least six months," Otterson said.

More than 10 percent of patients had grade 3 to 4 toxicities, including hematologic toxicity, febrile neutropenia, infection, sensory neuropathy, dyspnea and dehydration; researchers reported four deaths as grade 5 toxicities. "This combination treatment should be an option, particularly for patients with squamous histology who have limited alternative options," Otterson said.

American Association for Cancer Research

Related Bevacizumab Current Events and Bevacizumab News Articles

Time to tumor growth helps predict survival benefit of Bevacizumab for patients with metastatic colorectal cancer
Certara™, a leading provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through drug development, announced that its Pharsight Consulting Services has developed a mathematical model of tumor growth inhibition, which when combined with baseline prognostic factors, predicts treatment effect with bevacizumab for patients with metastatic colorectal cancer.

2-step ovarian cancer immunotherapy made from patients' own tumor shows promise
As many as three quarters of advanced ovarian cancer patients appeared to respond to a new two-step immunotherapy approach -- including one patient who achieved complete remission.

Study: Evidence Supports Blocking Immune Response to Enhance Viral Therapy against Solid Tumors
Following several years of study, investigators have found more evidence that viral therapy to treat solid tumors can be enhanced by blocking the body's natural immune response.

Two-Step Immunotherapy Attacks Advanced Ovarian Cancer, Penn Medicine Researchers Report
Most ovarian cancer patients are diagnosed with late stage disease that is unresponsive to existing therapies.

Mayo Clinic-led Study Unravels Biological Pathway That Controls the Leakiness of Blood Vessels
A research team led by scientists at Mayo Clinic in Florida have decoded the entire pathway that regulates leakiness of blood vessels - a condition that promotes a wide number of disorders, such as heart disease, cancer growth and spread, inflammation and respiratory distress.

Researchers develop non-invasive technique for predicting patients' response to chemotherapy
Researchers have developed a non-invasive way of predicting how much of a cancer-killing drug is absorbed by a tumour.

Combination treatment may improve survival of breast cancer patients with brain metastases
Adding an angiogenesis inhibitor to treatment with a HER2-inhibiting drug could improve outcomes for patients with HER2-positive breast cancer who develop brain metastases.

Phase III data in treatment of renal cell carcinoma reported
New results from phase III trials exploring treatment options for patients with advanced renal cell carcinoma were released at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.

Metastatic breast cancer: Bevacizumab slows progression, but has no impact on survival
The cancer drug bevacizumab (Avastin®) offers only a modest benefit in delaying disease progression in patients with advanced stage breast cancer, according to a systematic review by Cochrane researchers.

USC Norris Clinicians Discuss Cancer Research Results
USC Norris Comprehensive Cancer Center physician-researchers collaborated on more than 70 research projects presented at the 2012 annual meeting of the American Society of Clinical Oncology (ASCO) this month.

---

More Bevacizumab Current Events and Bevacizumab News Articles

---